RU2375356C2 - ПРОИЗВОДНЫЕ ИМИДАЗОЛА В КАЧЕСТВЕ ИНГИБИТОРОВ TAFIa - Google Patents

ПРОИЗВОДНЫЕ ИМИДАЗОЛА В КАЧЕСТВЕ ИНГИБИТОРОВ TAFIa Download PDF

Info

Publication number
RU2375356C2
RU2375356C2 RU2006141246/04A RU2006141246A RU2375356C2 RU 2375356 C2 RU2375356 C2 RU 2375356C2 RU 2006141246/04 A RU2006141246/04 A RU 2006141246/04A RU 2006141246 A RU2006141246 A RU 2006141246A RU 2375356 C2 RU2375356 C2 RU 2375356C2
Authority
RU
Russia
Prior art keywords
phenyl
unsubstituted
independently
alkyl
imidazol
Prior art date
Application number
RU2006141246/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2006141246A (ru
Inventor
Кристофер КАЛЛУС (DE)
Кристофер КАЛЛУС
Хольгер ХАЙЧ (DE)
Хольгер Хайч
Андреас ЛИНДЕНШМИДТ (DE)
Андреас Линденшмидт
Свен ГРЮНЕБЕРГ (DE)
Свен Грюнеберг
Хауке СИЛЛАТ (DE)
Хауке Силлат
Original Assignee
Санофи-Авентис Дойчланд Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34964308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2375356(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Санофи-Авентис Дойчланд Гмбх filed Critical Санофи-Авентис Дойчланд Гмбх
Publication of RU2006141246A publication Critical patent/RU2006141246A/ru
Application granted granted Critical
Publication of RU2375356C2 publication Critical patent/RU2375356C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2006141246/04A 2004-04-22 2005-04-07 ПРОИЗВОДНЫЕ ИМИДАЗОЛА В КАЧЕСТВЕ ИНГИБИТОРОВ TAFIa RU2375356C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004020186A DE102004020186A1 (de) 2004-04-22 2004-04-22 Heterocyclylessigsäuren als Inhibitoren von TAFla
DE102004020186.2 2004-04-22

Publications (2)

Publication Number Publication Date
RU2006141246A RU2006141246A (ru) 2008-06-10
RU2375356C2 true RU2375356C2 (ru) 2009-12-10

Family

ID=34964308

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006141246/04A RU2375356C2 (ru) 2004-04-22 2005-04-07 ПРОИЗВОДНЫЕ ИМИДАЗОЛА В КАЧЕСТВЕ ИНГИБИТОРОВ TAFIa

Country Status (34)

Country Link
EP (2) EP1864979B1 (cg-RX-API-DMAC10.html)
JP (1) JP4939401B2 (cg-RX-API-DMAC10.html)
KR (1) KR101162047B1 (cg-RX-API-DMAC10.html)
CN (1) CN100572376C (cg-RX-API-DMAC10.html)
AR (1) AR053302A1 (cg-RX-API-DMAC10.html)
AT (2) ATE523505T1 (cg-RX-API-DMAC10.html)
AU (1) AU2005238144B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0510159A (cg-RX-API-DMAC10.html)
CA (1) CA2563401C (cg-RX-API-DMAC10.html)
CR (1) CR8650A (cg-RX-API-DMAC10.html)
CY (1) CY1108087T1 (cg-RX-API-DMAC10.html)
DE (2) DE102004020186A1 (cg-RX-API-DMAC10.html)
DK (1) DK1740569T3 (cg-RX-API-DMAC10.html)
EC (1) ECSP066941A (cg-RX-API-DMAC10.html)
ES (1) ES2299026T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20080099T3 (cg-RX-API-DMAC10.html)
IL (1) IL178672A (cg-RX-API-DMAC10.html)
MA (1) MA28543B1 (cg-RX-API-DMAC10.html)
MY (1) MY140903A (cg-RX-API-DMAC10.html)
NI (1) NI200600217A (cg-RX-API-DMAC10.html)
NO (1) NO20065320L (cg-RX-API-DMAC10.html)
NZ (1) NZ550757A (cg-RX-API-DMAC10.html)
PE (1) PE20060172A1 (cg-RX-API-DMAC10.html)
PL (1) PL1740569T3 (cg-RX-API-DMAC10.html)
PT (1) PT1740569E (cg-RX-API-DMAC10.html)
RS (1) RS50553B (cg-RX-API-DMAC10.html)
RU (1) RU2375356C2 (cg-RX-API-DMAC10.html)
SI (1) SI1740569T1 (cg-RX-API-DMAC10.html)
TN (1) TNSN06341A1 (cg-RX-API-DMAC10.html)
TW (1) TWI359016B (cg-RX-API-DMAC10.html)
UA (1) UA87306C2 (cg-RX-API-DMAC10.html)
UY (1) UY28868A1 (cg-RX-API-DMAC10.html)
WO (1) WO2005105781A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200607668B (cg-RX-API-DMAC10.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ577312A (en) 2006-12-06 2012-02-24 Sanofi Aventis Urea and sulfamide derivatives as tafia inhibitors
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2008100459A1 (en) * 2007-02-13 2008-08-21 Schering Corporation Derivatives and analogs of chroman as functionally selective alpha2c adrenoreceptor agonists
AU2008279447A1 (en) * 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
EP2262783A2 (en) * 2008-02-21 2010-12-22 Sanofi-Aventis Covalently binding imaging probes
MX2010012793A (es) * 2008-06-06 2010-12-14 Sanofi Aventis Derivados de urea macrociclicos y de sulfamida como inhibidores de tafia.
AU2009310841A1 (en) 2008-10-29 2010-05-06 Taisho Pharmaceutical Co., Ltd. Compounds having TAFIa inhibitory activity
US8865906B2 (en) * 2009-05-15 2014-10-21 Sanofi Process for the preparation of a compound useful as an inhibitor of TAFIa
FR2947266B1 (fr) * 2009-06-26 2011-06-17 Servier Lab Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2483281B1 (en) 2009-10-01 2014-06-04 Cymabay Therapeutics, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
KR20130006620A (ko) 2010-03-18 2013-01-17 다이이찌 산쿄 가부시키가이샤 시클로프로판카르복실산 유도체
SG10201502026XA (en) 2010-03-18 2015-05-28 Daiichi Sankyo Co Ltd Cycloalkyl-substituted imidazole derivative
WO2012062730A1 (en) 2010-11-11 2012-05-18 Sanofi Process for the preparation of 3-(6-amino-pyridin-3yl)-2-acrylic acid derivatives
EP2782576B1 (en) * 2011-11-25 2016-05-18 Sanofi Sodium salt of (r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid
EP2782575B1 (en) 2011-11-25 2016-04-20 Sanofi Crystalline salts of r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid
US9156815B2 (en) 2011-11-25 2015-10-13 Sanofi Salt of (R)-3-(6-amino-pyridin-3-yl)-2-(1-Cyclohexyl-1H-imidazol-4-yl) ethyl propionate
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
RU2015156612A (ru) * 2013-06-10 2017-07-17 Санофи Макроциклические производные мочевины в качестве ингибиторов tafia, их получение и их применение в качестве фармацевтических средств
US20190117624A1 (en) 2016-03-29 2019-04-25 Daiichi Sankyo Company, Limited Therapeutic agent for inflammatory bowel diseases
WO2018026890A1 (en) 2016-08-03 2018-02-08 Cymabay Therapeutics Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003013526A1 (en) * 2001-08-08 2003-02-20 Merck & Co. Inc. Anticoagulant compounds
RU2001120723A (ru) * 1998-12-24 2003-06-27 Фудзисава Фармасьютикал Ко., Лтд. Производные имидазола и их медицинское применение

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20012338A3 (cs) * 1998-12-24 2001-12-12 Fujisawa Pharmaceutical Co., Ltd. Imidazolové sloučeniny
CA2472239A1 (en) 2002-01-22 2003-07-31 Pfizer Inc. 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2001120723A (ru) * 1998-12-24 2003-06-27 Фудзисава Фармасьютикал Ко., Лтд. Производные имидазола и их медицинское применение
WO2003013526A1 (en) * 2001-08-08 2003-02-20 Merck & Co. Inc. Anticoagulant compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BARROW et al, J. MED. CHEM., v.46, 2003, p.5294-5297. *

Also Published As

Publication number Publication date
UY28868A1 (es) 2005-11-30
UA87306C2 (en) 2009-07-10
TW200602325A (en) 2006-01-16
ZA200607668B (en) 2008-03-26
KR20070007346A (ko) 2007-01-15
SI1740569T1 (sl) 2008-06-30
PT1740569E (pt) 2008-03-31
ES2299026T3 (es) 2008-05-16
CR8650A (es) 2007-12-04
RS50553B (sr) 2010-05-07
HK1101823A1 (zh) 2007-10-26
NZ550757A (en) 2010-06-25
CA2563401A1 (en) 2005-11-10
ECSP066941A (es) 2006-12-20
DE102004020186A1 (de) 2005-11-17
HRP20080099T3 (en) 2008-03-31
EP1740569A1 (de) 2007-01-10
JP2007533672A (ja) 2007-11-22
EP1864979A1 (de) 2007-12-12
IL178672A (en) 2011-08-31
BRPI0510159A (pt) 2007-10-02
PL1740569T3 (pl) 2008-07-31
TNSN06341A1 (en) 2008-02-22
KR101162047B1 (ko) 2012-07-04
AU2005238144A1 (en) 2005-11-10
JP4939401B2 (ja) 2012-05-23
PE20060172A1 (es) 2006-03-31
MA28543B1 (fr) 2007-04-03
AU2005238144B2 (en) 2010-08-26
EP1740569B1 (de) 2008-02-20
NI200600217A (es) 2008-06-17
CN1950357A (zh) 2007-04-18
CN100572376C (zh) 2009-12-23
CY1108087T1 (el) 2014-02-12
AR053302A1 (es) 2007-05-02
IL178672A0 (en) 2007-02-11
TWI359016B (en) 2012-03-01
WO2005105781A1 (de) 2005-11-10
EP1864979B1 (de) 2011-09-07
RU2006141246A (ru) 2008-06-10
NO20065320L (no) 2007-01-12
ATE386737T1 (de) 2008-03-15
DK1740569T3 (da) 2008-06-02
CA2563401C (en) 2012-08-07
DE502005002927D1 (de) 2008-04-03
MY140903A (en) 2010-01-29
ATE523505T1 (de) 2011-09-15

Similar Documents

Publication Publication Date Title
JP4939401B2 (ja) TAFIa阻害剤として用いるイミダゾール誘導体
JP4053597B2 (ja) 置換n―[(アミノイミノメチル又はアミノメチル)フェニル]プロピルアミド
JP4861306B2 (ja) Xa因子阻害剤としてのピロール誘導体
SK160697A3 (en) Substituted derivatives of (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino)-n- -[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
CZ173398A3 (cs) Inhibitory metaloproteinasy, farmaceutické prostředky je obsahující a jejich farmaceutické použití, způsob a meziprodukty pro jejich výrobu
US8044208B2 (en) Imidazole derivatives as inhibitors of TAFIa
WO2002060894A2 (en) Sulfonamide lactam inhibitors of factor xa
US8710232B2 (en) Imidazole derivatives used as TAFIa inhibitors
DK2104497T3 (en) SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA
WO2006071775A2 (en) Novel compounds useful for bradykinin b1 receptor antagonism
JP2005506970A (ja) 置換イソインドール類およびそれらの使用
KR20090053813A (ko) 응고 인자 IXa 억제제로 사용되는 타르트레이트 유도체
BRPI0509256B1 (pt) Derivados de pirrolidina-3,4-dicarboxamida que inibem o fator xa de coagulação
PT1575942E (pt) Compostos possuindo efeito de inibição selectivo sobre a gsk3
JP4861179B2 (ja) マトリックスメタロプロテイナーゼの阻害剤として使用される二環式イミノ酸誘導体
EP1409479A2 (en) 1-glycinyl-4-(1-methylpiperidin-4-yl)piperazines and -piperidines as factor xa antagonists
MXPA06011067A (en) Imidazole derivatives used as tafia inhibitors
KR101373533B1 (ko) 인자 Xa 억제제로서의 헤테로아릴-카복실산(설파모일 알킬)아미드 유도체
KR101315788B1 (ko) 매트릭스 메탈로프로테이나제의 억제제로서 사용하기 위한테트라하이드로푸란 유도체
HK1101823B (en) Imidazole derivatives used as tafia inhibitors
JPWO2000078747A1 (ja) アシルヒドラジン誘導体、その製造法及び用途
HK1117157B (en) Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide - derivatives as factor xa inhibitors

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20150408